Baidu
map

JCEM:“抵消”糖皮质激素骨折副作用的尝试成功了?

2018-02-05 石岩 环球医学

糖皮质激素作为一种广泛用于多种疾病的“万能药”,可谓让人又喜又忧。喜的是其具有强大的抗炎和免疫抑制作用,忧的是它被认为会引起继发性骨质疏松症。这使得医生对骨折高危人群使用糖皮质激素变得更加小心翼翼,那么有没有一种方法能够让大家不必担心骨折风险而放心大胆地使用糖皮质激素呢?

糖皮质激素作为一种广泛用于多种疾病的“万能药”,可谓让人又喜又忧。喜的是其具有强大的抗炎和免疫抑制作用,忧的是它被认为会引起继发性骨质疏松症。这使得医生对骨折高危人群使用糖皮质激素变得更加小心翼翼,那么有没有一种方法能够让大家不必担心骨折风险而放心大胆地使用糖皮质激素呢?

秉着“对症治疗”的原则,科学家们猜想通过联合抗骨质疏松药物或许能抵消糖皮质激素的副作用。考虑到目前没有临床试验能够证明这一点,2018年1月,瑞典科学家在《Journal of Clinical Endocrinology & Metabolism》上发表了一篇回顾性队列研究,旨在考察阿仑膦酸钠对口服糖皮质激素的老年人非椎体骨折风险的影响。

研究人员使用了瑞典国家登记处的回顾性队列研究,确定了2006~2011年开始口服糖皮质激素治疗(强的松≥2.5mg/d或≥91天的同等剂量)的≥50岁的患者(n=3347959)。最后的分析纳入了16890名阿仑膦酸钠服用者和16890名阿仑膦酸钠未服用者,研究人员采用随时间依赖的倾向性得分进行匹配。

该研究的主要结局为未预先设定的非椎体骨折。

在中位随访14.5个月期间,在阿仑膦酸钠服用者中非椎体骨折的发生率为每2例/100人年,在阿仑膦酸钠未服用者中为2.4例/100人年。这种差异表明在阿仑膦酸钠服用者中风险降低了16%(风险比为0.84)。

特异性地针对髋部骨折,阿仑膦酸钠服用者比未服用者的髋部骨折发生率要低34%(风险比为0.66)。在接受高剂量糖皮质激素治疗的患者中服用阿仑膦酸钠与较低的非椎体骨折风险之间的相关性最为明显。

由此可见,服用阿仑膦酸钠与非椎体骨折(包括髋部骨折)的风险降低相关。在临床试验的meta分析中也有类似相关性的报道,但缺少统计学意义。

由于这是一项观察性研究,所报告的相关性不一定是因果关系。但是,既往关于双膦酸盐临床试验的两个荟萃分析显示非椎骨骨折风险降低。而该项广泛的观察研究似乎合理估计了阿仑膦酸钠“抵消”糖皮质激素副作用效果的大小。

必须要说明的是,尽管这种方法避免了基线特征的差异,但骨折风险降低有一部分可能与治疗无关。除此之外,研究可能导致对阿仑膦酸钠的效果期望过高,实际上它的影响应当是渐进式的。

在这项研究中,接受糖皮质激素治疗数月后再服用阿仑膦酸钠的患者骨折风险并未降低。与此相反,之前有研究表明,不管之前的糖皮质激素治疗持续多久,阿仑膦酸钠对骨密度都有好处。这可能是由于研究中的混淆因素造成的,但也因此,更建议将阿仑膦酸钠作为预防性治疗。

相信在不久的将来会找到更好的方法来驾驭糖皮质激素这一双刃剑。

原始出处:

Jonathan Bergman, Anna Nordstrm, Peter Nordstrm. Alendronate Use and the Risk of Nonvertebral Fracture During Glucocorticoid Therapy: A Retrospective Cohort Study. The Journal of Clinical Endocrinology & Metabolism, Volume 103, Issue 1, 1 January 2018, Pages 306–313, https://doi.org/10.1210/jc.2017-01912.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1824272, encodeId=db6618242e299, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Nov 01 08:33:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777764, encodeId=4cd91e77764ae, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Apr 07 04:33:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701202, encodeId=42021e01202b9, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Tue May 22 20:33:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063146, encodeId=c7d02063146ba, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 31 16:33:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600317, encodeId=dd75160031ed9, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Wed Feb 07 05:33:00 CST 2018, time=2018-02-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1824272, encodeId=db6618242e299, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Nov 01 08:33:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777764, encodeId=4cd91e77764ae, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Apr 07 04:33:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701202, encodeId=42021e01202b9, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Tue May 22 20:33:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063146, encodeId=c7d02063146ba, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 31 16:33:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600317, encodeId=dd75160031ed9, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Wed Feb 07 05:33:00 CST 2018, time=2018-02-07, status=1, ipAttribution=)]
    2018-04-07 smallant2015
  3. [GetPortalCommentsPageByObjectIdResponse(id=1824272, encodeId=db6618242e299, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Nov 01 08:33:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777764, encodeId=4cd91e77764ae, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Apr 07 04:33:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701202, encodeId=42021e01202b9, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Tue May 22 20:33:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063146, encodeId=c7d02063146ba, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 31 16:33:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600317, encodeId=dd75160031ed9, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Wed Feb 07 05:33:00 CST 2018, time=2018-02-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1824272, encodeId=db6618242e299, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Nov 01 08:33:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777764, encodeId=4cd91e77764ae, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Apr 07 04:33:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701202, encodeId=42021e01202b9, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Tue May 22 20:33:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063146, encodeId=c7d02063146ba, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 31 16:33:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600317, encodeId=dd75160031ed9, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Wed Feb 07 05:33:00 CST 2018, time=2018-02-07, status=1, ipAttribution=)]
    2018-10-31 achengzhao
  5. [GetPortalCommentsPageByObjectIdResponse(id=1824272, encodeId=db6618242e299, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Nov 01 08:33:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777764, encodeId=4cd91e77764ae, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Apr 07 04:33:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701202, encodeId=42021e01202b9, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Tue May 22 20:33:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063146, encodeId=c7d02063146ba, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 31 16:33:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600317, encodeId=dd75160031ed9, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Wed Feb 07 05:33:00 CST 2018, time=2018-02-07, status=1, ipAttribution=)]

相关资讯

J INTERN MED:亚临床甲状腺功能异常与骨密度改变的关系!

由此可见,在成人中,SHyper与股骨颈骨丢失增加有关,可能是导致骨折风险增加的原因。

JAMA Pediatr:吸入型糖皮质激素增加哮喘儿童骨折风险吗?

目前,医生治疗儿童哮喘会因为担心骨折风险而限制使用吸入型糖皮质激素。2018年1月,发表在《JAMA Pediatr》的一项由加拿大科学家进行的巢氏病例对照研究中,考察了吸入型糖皮质激素使用和哮喘儿童骨折之间的相关性。

Semin Arthritis Rheu:中轴型脊柱关节炎中骨质疏松和骨折的患病率及危险因素

对Ax-SpA患者的骨质疏松症评估中,应考虑饮酒、使用类固醇以及低水平25-OH-维生素D。

J Bone Miner Res:警惕:糖尿病还可能对骨有这些影响!

除了损害心血管和肾功能外,已知2型糖尿病是骨折的危险因素 - 但糖尿病如何使骨骼更脆弱尚不清楚。

Radiology:莫要忽视肋软骨骨折,防千里之堤溃于蚁穴!

本研究旨在评价胸部钝器伤行全身CT检查肋软骨(CC)骨折的发病率及CC骨折分布、合并伤、损伤机制、报告准确性及其对30天死亡率的影响,研究人员将结果发表在Radiology上。本研究共查阅了36个月来胸部钝器伤行全身CT的患者资料,并由另一位阅片者对胸部创伤CT进行分析。在1461例行全身CT检查的患者中,39% (574 / 1461)具有胸部损伤(男性为74.0% [425 / 574],平均

NEJM:与百日咳杆菌感染有关的肋骨骨折-病例报道

该患者接受阿奇霉素治疗,并接受手术治疗修复发生骨折的肋骨和胸壁的相关疝。该患者完全康复出院。医务人员对其家庭接触者以及几名曾与患者密切接触的医务人员采用阿奇霉素进行暴露后预防。

Baidu
map
Baidu
map
Baidu
map